Opendata, web and dolomites

EURO SHOCK SIGNED

Testing the value of a novel strategic approach and its cost efficacy to improve the poor outcomes in Cardiogenic Shock

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EURO SHOCK project word cloud

Explore the words cloud of the EURO SHOCK project. It provides you a very rough idea of what is the project "EURO SHOCK" about.

cardiogenic    true    clear    return    exists    health    12    clinical    phase3    therapies    innovative    ill    drugs    burden    scientists    delivering    admissions    transfer    mechanistic    imaging    time    sub    heart    sick    membrane    chronic    leave    socio    sme    70    renowned    magnetic    hoc       healthcare    risk    specialised    morbidity    ad    suggests    cardiac    re    spiral    informing    alone    randomised    multidisciplinary    42    guidelines    mortality    efficacy    worse    suffering    survivors    trial    decline    benefit    versus    cgs    death    irrecoverable    groups    statisticians    economists    europe    protocols    ecg    strategy    standard    females    recurrent    intervention    therapeutic    medical    care    technologies    attack    too    significantly    patients    life    full    pa    expensive    data    providers    reducing    disease    spiralling    interventions    rate    economic    reduce    halt    unmet    unacceptably    framework    elderly    physician    core    extracorporeal    outcomes    attacks    networks    oxygenation    extremely    gt    resonance    ecmo    shock    incidence   

Project "EURO SHOCK" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF LEICESTER 

Organization address
address: UNIVERSITY ROAD
city: LEICESTER
postcode: LE1 7RH
website: www.le.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.euroshock-study.eu
 Total cost 6˙499˙572 €
 EC max contribution 6˙499˙572 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF LEICESTER UK (LEICESTER) coordinator 946˙312.00
2    UNIVERSITY OF GLASGOW UK (GLASGOW) participant 1˙327˙843.00
3    CHALICE MEDICAL LIMITED UK (WORKSOP) participant 793˙750.00
4    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 517˙400.00
5    ACCELOPMENT AG CH (ZUERICH) participant 421˙171.00
6    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 360˙812.00
7    CENTRE EUROPEEN DE RECHERCHE CARDIOVASCULAIRE CERC FR (MASSY) participant 320˙000.00
8    UNIVERSITETSSYKEHUSET NORD-NORGE HF NO (TROMSO) participant 289˙253.00
9    UNIVERSITY OF EAST ANGLIA UK (NORWICH) participant 267˙717.00
10    DEUTSCHES HERZZENTRUM MUNCHEN DE (MUNICH) participant 252˙500.00
11    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 252˙500.00
12    UNIVERSITAIR ZIEKENHUIS ANTWERPEN BE (EDEGEM) participant 252˙500.00
13    AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII IT (BERGAMO) participant 252˙375.00
14    UNIVERSITAT POLITECNICA DE CATALUNYA ES (BARCELONA) participant 148˙440.00
15    PAULA STRADINA KLINISKA UNIVERSITATES SLIMNICA LV (RIGA) participant 82˙500.00
16    UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET NO (TROMSO) participant 14˙496.00

Map

 Project objective

Heart attacks are common and can leave survivors suffering cardiogenic shock (CGS), with its extremely high risk of early death (42% versus 4% for non-CGS) and high incidence of chronic heart failure, with its associated socio-economic disease burden (ill-health, recurrent heart failure admissions, no return to full time activities, need for expensive therapeutic devices and life-long drugs). Outcomes from CGS are even worse in, females, the elderly (mortality>70%) and high risk sub-groups. The incidence of CGS in Europe alone is >50 000 patients pa. This unacceptably high mortality/morbidity rate represents a true unmet clinical need. No clear strategy exists to improve outcomes, with ad hoc therapies given too late in a spiralling, irrecoverable process. EURO SHOCK aims to improve outcomes for CGS patients. At its core is a robust phase3 randomised trial comparing a novel strategy of very early use of ECMO (Extracorporeal Membrane Oxygenation) to current standard of care. Evidence suggests very early ECMO will halt the spiral of decline and so significantly reduce 12 month death rate and need for heart failure re-admissions. Since both costs of CGS, and ECMO are high a health-economic cost efficacy analysis will be core. A cardiac magnetic resonance imaging sub-study will test novel protocols in sick patients and provide mechanistic data. We will test transfer networks for CGS patients and analyse ECG data to determine which patients benefit most from early transfer. Our multidisciplinary consortium comprises renowned physician-scientists, statisticians, health economists and technology providers, including specialised ECMO SME. EURO SHOCK will impact on heart attack survivors, healthcare providers and Europe`s medical technology sector by 1) reducing healthcare costs associated with CGS 2) provide novel cost effective framework for cardiac interventions 3) delivering innovative healthcare technologies and 4) informing guidelines for effective CGS intervention.

 Deliverables

List of deliverables.
Dissemination and Outreach Plan (DOP) Documents, reports 2019-10-15 13:15:19
Statistical analysis plan Documents, reports 2019-10-15 13:15:26
EURO SHOCK website Websites, patent fillings, videos etc. 2019-10-15 13:15:18
Training materials for sites in all relevant health economic aspects Other 2019-10-15 13:15:27
Trial governance report Documents, reports 2019-10-15 13:15:21

Take a look to the deliverables list in detail:  detailed list of EURO SHOCK deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EURO SHOCK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EURO SHOCK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More